P420B

antibody from Invitrogen Antibodies

Targeting: IL1B IL-1B, IL1-BETA, IL1F2

Provider product page for P420B

Western blot

Immunocytochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [29]
Comments [0]
Validations
Western blot [1]
Immunocytochemistry [1]
Other assay [13]

Submit

Product number: P420B - Provider product page
Provider: Invitrogen Antibodies
Product name: IL-1 beta Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: P420B targets IL-1 beta in ELISA, IHC, Neu, and WB applications and shows reactivity with Human, mouse, and Non-human primate samples.
Concentration: 1.0 mg/mL

IL1B protein structure - P420B shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 2 FIGURE Intragastric treatment with gliadin p31-43 peptide induces apoptosis, pyroptosis, and necroptosis . ( A ) Left: representative images of caspase-3 staining of small intestine of C57BL/6 mice 16 h after intragastric administration of PBS or 20 µg gliadin p31-43. DAPI staining for nuclei (blue), caspase-3 in red. Fluorescence intensity of caspase-3 staining in histological sections of small intestine 16 h after administration of p31-43 ( n = 5) and in controls ( n = 4). **** P < 0.0001. Student's unpaired t -test. Right: representative Western blot analysis of procaspase-3 and cleaved caspase-3 in small intestine 16 h after administration of p31-43 or PBS. Quantitative analysis of Western blot bands expressed as the ratio of cleaved caspase-3:procaspase-3 in p31-43 ( n = 4) or PBS ( n = 4)-treated mice. ** P < 0.01; Student's unpaired t -test. ( B ) Left: representative images of IL-1beta staining of small intestine of C57BL/6 mice 16 h after intragastric administration of PBS or 20 µg gliadin p31-43. DAPI staining for nuclei (blue), IL-1beta in red. Fluorescence intensity of IL-1beta staining in histological sections of small intestine 16 h after administration of p31-43 ( n = 4) and in controls ( n = 6). * P < 0.05; Student's unpaired t -test. Right: representative Western blot analysis of IL-1beta activation in small intestine 16 h after administration of p31-43 or PBS. Quantitative analysis expressed as the ratio of mature IL-1beta: pro-IL-1beta 16 h af

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 5 FIGURE Induction of pyroptosis in p31-43-treated mice . ( A ) Representative Western blot analysis and quantitative analysis of caspase-1 activation expressed as the ratio of cleaved caspase-1:procaspase-1 in epithelial and lamina propria fractions 16 h after administration of p31-43 ( n = 8) or PBS ( n = 8). ** P < 0.01; Student's unpaired t -test. ( B ) Representative Western blot analysis and quantitative analysis of IL-1beta activation expressed as the ratio of mature IL-1beta:pro-IL-1beta in epithelial and lamina propria fractions 16 h after administration of p31-43 ( n = 8) or PBS ( n = 8). * P < 0.05; Student's unpaired t -test

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Exenatide attenuated NASH by inhibiting the pyroptosis signaling pathway in vitro . (A) A representative Oil Red O staining image showed that exenatide attenuated NASH. The numbers above each picture (shown in red) indicated the relative staining intensity as quantified by ImageJ. (B) Representative immunofluorescence images of GSDMD and GSDMD protein expression levels measured by western blotting. (C) Representative immunofluorescence images of NLRP3, caspase-1, and IL-1beta. NLRP3, caspase-1, and IL-1beta. Protein expression levels were measured by western blotting. For panel (B, C) , the numbers below the images (shown in red) indicated the relative fluorescence intensity as quantified by ImageJ. Two subcultures were used for each western blot markers and the experiment was repeated 2-3 times. *p < 0.1; ***p < 0.001. Data are expressed as the mean +- SEM.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 PA-milk diet induced inflammation in the gut and skin. ( a ) Representative immunofluorescence staining for NLRP3 (red), IL-1beta (red) and Bodipy FL C16 (green) in the small intestine of mice at 15 weeks post-weaning (p.w.). Nuclei were stained with DAPI (blue). Scale bars, 100 um. ( b ) Oil red O lipid staining of the small intestines of mice at 15 p.w. ELISA quantitation of IL-1beta (pg/ml) in ( c ) small intestine (SI) extracts and ( d ) whole tissue culture taken from mice at indicated p.w. (n = 5 mice/group). SI extracts were obtained by lysis treatment and sonication. For whole tissue culture, small intestine was cut into small pieces and cultured on 24-well tissue dish for 18 h before the collection of supernatant for IL-1beta quantitation. ( e ) ELISA quantitation of GDNF in small intestine extracts at indicated p.w. ( f ) Percentages of ILC3-RET expression in IEL and LP of mice at 15 weeks p.w. (n = 8 mice/group). * P < 0.05, ** P < 0.01, one-way ANOVA. Data are analyzed with Prism8 (version 8.4.3, https://www.graphpad.com/scientific-software/prism ), and ImageJ (version 1.53, https://imagej.nih.gov/ij/index.html ).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 DNMT2/TRDMT1 gene knockout-mediated senescence-associated secretory phenotype (SASP) ( A , B ) in U-251 MG glioblastoma cells treated with DOX or ETOPO. ( A ) The levels of NF-kappaB, IL-1beta, IL-6 and IL-8 are expressed as relative fluorescence units (RFU). Box and whisker plots are shown, n = 3, *** p < 0.001, ** p < 0.01, * p < 0.05 compared to CTR (ANOVA and Dunnett's a posteriori test), ### p < 0.001, ## p < 0.01, # p < 0.05 compared to C-NIC cells at the same culture conditions (ANOVA and Tukey's a posteriori test). ( B ) NF-kappaB, IL-1beta, IL-6 and IL-8 immunostaining (red). Representative microphotographs are shown, objective 20x, nucleus staining (blue), RESPONSE, representative DOX or ETOPO treatment. CTR, control conditions; DOX, doxorubicin treatment; ETOPO, etoposide treatment; AZA, azacytidine treatment; MIX, azacytidine post-treatment; C-NIC, control cells with unmodified levels of DNMT2/TRDMT1 containing control plasmid; D-NIC, cells with DNMT2/TRDMT1 gene knockout containing dedicated DNMT2 double nickase plasmid.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 10 ( A , E ) Interleukin-1 beta (IL-1 beta) (35 kDa), ( B , F ) interleukin-6 (IL-6) (24 kDa), ( C , G ) tumor necrosis factor- alpha (TNF-alpha) (25 kDa), ( D , H ) type 2 TNF receptor (TNFR2) (75 kDa) levels in cardiac tissue evaluated by Western blotting, in infant DOX-treated (I-DOX) and control mice (I-Control), and adult mice exposed to a cumulative dose of 18.0 mg/kg DOX (A-DOX) and respective controls (A-Control). Values are expressed as mean +- SD and were obtained from 6 (infant) and 6-7 (adult) animals from each treatment group. Statistical comparisons were made using Student's t -test: ** p < 0.01, DOX vs. control. OD: optic density. Protein loading was confirmed by the Ponceau S staining ( Figure S3 ).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4. IRF2 silencing attenuates GSDMD-induced pyroptosis in vitro . (A) IRF-2 expression in H9c2 cells stimulated by hypoxia (6, 12, 24 and 48 h) was detected by reverse transcription-quantitative PCR. *P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIG. 13. Transcriptomic analysis reveals that ferryl hemoglobin polarizes macrophages into a proinflammatory-like phenotype. (A, B) RNA-seq transcriptomic analysis was performed on human macrophages treated with ferrylHb (10 mu M ) for 8 h ( n = 4/group). (A) Heatmap of the 50 most-changed DE genes is shown in log 10 (FC). (B) M1 and M2 signatures are shown as a clustered heatmap in log 10 (FC). (C, D) Relative expression of (C) IL-1beta, TNF-alpha, CXCL8, (D) CD209, and IL-27RA were analyzed by real-time qPCR ( n = 3). (E) Protein expression of HO-1, H-ferritin, Pro-IL-1beta, IL-1beta, TNF-alpha and GAPDH was determined by Western blots in macrophages exposed to ferrylHb (10 mu M , 8-h ferrylHb treatment). ** p < 0.01; *** p < 0.001. DE, differentially expressed; FC, fold change. Color images are available online.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIG. 6. Ferryl hemoglobin-positive macrophages in carotid artery are positive for IL-1beta and TNF-alpha. Cross sections of a healthy carotid artery and atheromatous and hemorrhagic transformed lesions were shown. (A) Images demonstrated macrophages positive for both CD68 and IL-1beta in the atheromatous plaque and positive for ferrylHb, CD68, and IL-1beta in the hemorrhagic transformed lesions. Sections were stained with Hoechst 33258 for DNA ( blue ), an anti-ferrylHb antibody with Alexa Flour 488 secondary antibody for ferrylHb ( green ), an anti-CD68 antibody with Alexa Flour 568 secondary antibody for CD68 ( yellow ), and an anti-IL-1beta antibody with Alexa Flour 647 secondary antibody for IL-1beta ( red ). (B) Images demonstrated macrophages positive for both CD68 and TNF-alpha in the atheromatous plaque and positive for ferrylHb, CD68, and TNF-alpha in the hemorrhagic transformed lesions. Sections were stained with Hoechst 33258 for DNA ( blue ), an anti-ferrylHb antibody with Alexa Flour 488 secondary antibody for ferrylHb ( green ), an anti-CD68 antibody with Alexa Flour 568 secondary antibody for CD68 ( yellow ), and an anti-TNF-alpha antibody with Alexa Flour 647 secondary antibody for TNF-alpha ( red ). Images were taken using Leica TCS SP8 gated STED-CW nanoscopy. Images were deconvolved using Huygens Professional software. Representative image, N = 5. (C) Fluorescence intensity for ferrylHb ( n = 17), CD68 ( n = 20), IL-1beta ( n = 19), and TNF-alpha ( n = 15)

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: The mRNA expression of Interleukin 1beta (IL-1beta) (A, C) and Interleukin 18 (IL-18) (B, D) protein in placentae from female- and male-bearing pregnancies classed by delivery mode. For (A, B) , Data are presented as a 10-90 percentile interleaved box-and-whisker plot. The same letter above bars indicates that groups are not different from each other. A different letter above bars indicates that groups are different (all p < 0.05). Dark grey colour denotes placenta samples from female fetal sex; light grey colour denotes placenta samples from male fetal sex. (C, D) show representative images of staining with an IL-1beta antibody (molecular weight ~35 kDa) and an IL-18 antibody (molecular weight ~20 kDa), respectively. Below this is a representative image of stain-free Total Protein staining as a control. (Number of samples: unassisted vaginal (UV) = 6/fetal sex; labouring lower segment Caesarean section (LLSCS) = 4/fetal sex; prelabour lower segment Caesarean section (PLSCS) = 2/fetal sex).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Oral administration of p31-43 induces caspase 1 activation and production of mature IL-1beta. (A) Western blot analysis of mature IL-1beta and (B) caspase-1 and pro-caspase-1 quantification in whole small intestinal tissue from p31-43 or vehicle-fed mice 16 h after treatment. (C) IL-1beta/caspase 1 ratio of data shown in (A,B) . (D) Representative results of Western blots are shown. Results shown are means +- 1 SEM for 5 mice and are representative of two experiments. ** p < 0.01, *** p < 0.001, Student's t -test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Effects of PNU282, PNU120, their combination, or nicotine on IL-1beta (A,C) or IL-6 (B,D) levels in the blood of mice on days 7 and 14 after LPS injection (A,B) or on days 7 and 14, 2 months after LPS injection (C,D) . Each column corresponds to Mean +- SD, n = 5. (A,B) * p < 0.05; ** p < 0.005; *** p < 0.0005 compared to LPS; ## p < 0.005 compared to Ctrl. (C,D) * p < 0.05; ** p < 0.005; compared to Ctrl.